Spots Global Cancer Trial Database for Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
Official Title: A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours
Study ID: NCT01581060
Conditions
Interventions
Study Description
Brief Summary: The aim of part 1 of this study is to determine the optimal biological dose (OBD) and maximum tolerated dose (MTD) for WX-554 and the recommended dose/dose schedules for the chronic treatment in part 2. The aim of part 2 is to further determine the safety and tolerability of chronic treatment with WX-554.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Queen's University Belfast Cancer Centre, Belfast, , United Kingdom
Beatson West of Scotland Cancer Centre, Glasgow, , United Kingdom
St James' Institute of Oncology, Leeds, , United Kingdom
Christie NHS Foundation Trust, Oak Road Treatment Centre, Manchester, , United Kingdom
Sir Bobby Robson Cancer Trials Research Centre, Newcastle Upon Tyne, , United Kingdom
Contact Details
Name: Ruth Plummer, MD
Affiliation: Sir Bobby Robson Cancer Trials Research Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
